Liquid-Phase Droplets Inside Cells May Unlock Drugs for 'Undruggable' Proteins

Every cell in the body must continuously produce, fold, and destroy proteins to stay healthy — a balancing act known as proteostasis. When proteostasis breaks down, misfolded or toxic proteins accumulate, driving conditions ranging from neurodegeneration to cancer. Despite decades of drug development, many of the most disease-relevant proteins have remained stubbornly 'undruggable' by conventional small molecules or biologics.

This perspective article from researchers at Tsinghua University focuses on a newly appreciated mechanism: liquid-liquid phase separation (LLPS), in which proteins and nucleic acids spontaneously condense into membraneless, droplet-like compartments inside the cell. These biomolecular condensates are not random — they selectively concentrate the molecular machinery responsible for protein degradation, including ubiquitin-proteasome system components and autophagy regulators, enabling precise, location-specific protein clearance.

The authors review growing evidence that these condensates serve as dedicated hubs for proteostasis, organizing the spatial and temporal control of which proteins get degraded and when. Disruption of condensate formation or function appears to contribute directly to disease pathology, while properly functioning condensates help protect cells from protein toxicity.

The therapeutic implications are significant. By engineering or pharmacologically manipulating these condensates, it may become possible to direct the cell's own degradation machinery toward previously unreachable targets — proteins that lack clear binding pockets or active sites for traditional drugs. The authors position condensate-based degradation as a versatile platform for precision medicine.

This is a perspective article based on existing literature rather than original experimental data, so the mechanistic claims remain partly speculative. Translating condensate biology into clinical therapies faces considerable technical hurdles, including achieving cell-type specificity and avoiding disruption of normal condensate function. Nonetheless, the conceptual framework presented could meaningfully influence the next generation of targeted protein degradation strategies.